Previous 10 | Next 10 |
–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022– –Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023– –Faster release capsule cohort to be added to on-going Phase 2 trial...
Evelo Biosciences Inc. (NASDAQ:EVLO) traded today at a new 52-week high of $19.77. So far today approximately 9.4 million shares have been exchanged, as compared to an average 30-day volume of 305,000 shares. Evelo Biosciences Inc. (NASDAQ:EVLO) is currently priced 2.7% above its average...
CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today presented a late-breaking oral abstract on ...
Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q4 2021 Earnings Call Mar 24, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Call Transcript
Clinical-stage biotech, Evelo Biosciences (EVLO +17.7%), is trading higher Thursday after reporting its third consecutive quarterly earnings beat with its financials for 4Q 2021. Net loss for the quarter contracted ~1% YoY to $28.7 million as R&D expenses declined ~15% YoY to $18.9M....
Evelo Biosciences, Inc. (EVLO) Q4 2021 Earnings Conference Call March 24, 2022 8:30 AM ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Mark Bodmer - President of R&D, Chief Scientific Officer Jonathan Zung - Chief Development Officer Confer...
Evelo Biosciences press release (NASDAQ:EVLO): Q4 GAAP EPS of -$0.54 beats by $0.08. As of December 31, 2021, cash and cash equivalents were $68.4 million, as compared to cash and cash equivalents of $68.9 million as of December 31, 2020. For further details see: Evelo Biosciences GAAP ...
–Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 – –Positive data reported on faster release capsule– –Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2...
If you’re looking for the most exciting way to make money in the stock market today, penny stocks should be at the top of your list. These high-flying, low-priced names have become a mainstay for day traders and investors alike. The idea of “getting in early” tends to a...
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference ca...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
NASDAQ Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...